Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of satralizumab in MOG antibody-associated disease
jRCT2021220005Phase 3Active, not recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) comparing Satralizumab with Placebo (2 arms). Primary endpoint: Time to first adjudicated MOGAD relapse. Started Jan 2023; status: active, not recruiting.
02
Drugs
satralizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on jRCT2021220005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220005.